SLC response kinematics at 28 dpf. by Morgan Barnes (7876373)

“…<p>(A-B) C1 is the first C-bend performed. The angle and duration of the C1 bend is not significantly altered at this time point. …”

Minigene assay of rare missense VUS in exon 10. by Elina Mercier (22311151)

“…<p><b>(a)</b> Position of variants that were tested by minigene assay. …”

Isolation and characterization of the <i>clr4–1</i> mutant strain. by Ziyue Liu (381532)

“…Data are presented as mean ± SD from three independent experiments. Statistical significance was determined using a one-way ANOVA followed by Dunnett’s multiple comparison test, with WT as the reference sample (*<i>p</i> < 0.05 and **<i>p</i> < 0.01; N.S.: not significant).…”

Data Sheet 1_Comparison of the efficacy and safety of different growth factors in the treatment of diabetic foot ulcers: an updated network meta-analysis.docx by Jianzhou Tian (21596621)

“…Objective<p>This study aimed to evaluate the efficacy and safety of different growth factors (GFs) in the treatment of diabetic foot ulcers (DFUs) through a network meta-analysis.</p>Methods<p>A systematic search was conducted in PubMed, Embase, The Cochrane Library, and Web of Science to identify randomized controlled trials (RCTs) comparing GFs with standard of care (SOC) or comparing different GFs for the treatment of DFU. …”

Figure 2 from Loss of Sorting Nexin 10 Accelerates KRAS-Induced Pancreatic Tumorigenesis by Kohinoor Khan (22206206)

“…Statistically significant differences *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; and #, <i>P</i> < 0.001 are represented as mean ± SEM. MW, molecular weight; OD, optical density; PI-A, propidium iodide area.…”

Table 2_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”

Table 4_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”

Supplementary file 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”

Table 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”

Table 3_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

“…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”

<b>Differences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow up: Relation to Dysglycemia</b> by Nelly Mauras (8103110)

“…<p dir="ltr">Type 1 diabetes has detrimental effects in white matter microstructure. In a longitudinal study, we investigated if these reported findings change as children grow and enter puberty.…”

Table 1_Effect of cholecalciferol on immune and vascular function in non-diabetic chronic kidney disease.docx by Kajal Kamboj (12769602)

“…</p>Results<p>In total, 62 subjects were studied. The mean age was 44 ± 12 years with 58% men. TH1 cells decreased from 17% (9%, 27%) to 11% (6%, 16%) (p=0.002) and TH2 cells increased from 9% (5%, 16%) to 16% (10%, 27%) (p=0.001) after cholecalciferol treatment. …”

Figure 5 from Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma by Zelei Yang (18491142)

“…<b>A,</b> A cartoon demonstrating the experimental setup is shown. …”

Table 1_Differential resilience of chickpea’s reproductive organs to cold stress across developmental stages: insights into antioxidant strategies for enhanced fertility.docx by Deeksha Padhiar (21010250)

“…Exogenous supplementation with 1 mM ascorbate (AsA) and glutathione (GSH) significantly stimulated pollen germination in cold-stressed plants under in vitro conditions, with a greater effect observed in CS genotypes. …”

<b>Tirzepatide Associated with Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Cli... by Ellen M. Apperloo (20405468)

“…</p><p dir="ltr"><i>Conclusions:</i> In this post hoc analysis in people with type 2 diabetes, including those with chronic kidney disease, tirzepatide was associated with clinically relevant decreased UACR versus comparators, suggesting a potential kidney-protective effect.…”

Table 2_Differential resilience of chickpea’s reproductive organs to cold stress across developmental stages: insights into antioxidant strategies for enhanced fertility.docx by Deeksha Padhiar (21010250)

“…Exogenous supplementation with 1 mM ascorbate (AsA) and glutathione (GSH) significantly stimulated pollen germination in cold-stressed plants under in vitro conditions, with a greater effect observed in CS genotypes. …”

Supplementary file 1_Therapeutic efficacy and safety of Xuebijing in traumatic brain injury: systematic review and meta-analysis.docx by Yihan Sun (3432287)

“…Background<p>Traumatic brain injury (TBI) represents a major global health challenge. Several clinical studies have suggested that Xuebijing (XBJ)—a patented Chinese botanical drug preparation may confer neuroprotective and anti-inflammatory benefits in TBI. …”

Baseline characteristics of the study population. by Vatsala Rajendram (20691806)

“…<div><p>Background</p><p>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. …”

Patient disposition. by Vatsala Rajendram (20691806)

“…<div><p>Background</p><p>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. …”

Table 1_Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.docx by Zhifei Chen (1740625)

“…Participants were recruited from December 2021 to June 2022, with a follow-up period of 180 days. We evaluated humoral immune responses and their longevity by measuring the geometric mean titers (GMTs) of neutralizing antibodies against the SARS-CoV-2 virus at various time points post-boost. …”